mhurhangee/patent-ind-claim-en huggingface dataset:
A method, comprising: receiving system data associated with a target asset of an operational system, wherein the operations of the target asset are affected by the operations of an upstream asset and the operations of the target asset affect the operations of a downstream asset; determining at least one operational anomaly associated with the target asset based on the system data, wherein the operational anomaly is indicative of a difference in operations of the target asset with respect to standard operation; identifying a root cause variable associated with the at least one operational anomaly; determining a first remaining lifetime value for the root cause variable, the first remaining lifetime value representing a time to reach a limit threshold value associated with the root cause variable; determining a second remaining lifetime value for an asset health index representing an overall operational health of the target asset and associated with the target asset based on the first remaining lifetime value, the second remaining lifetime value representing a remaining useful lifetime for the target asset and, wherein the asset health index associated with the target asset impacts operational health of the at least one of the upstream asset and downstream asset; and initiating at least one of a maintenance and repair processes for the target asset based on the first remaining lifetime value and the second remaining lifetime value. receiving system data associated with a target asset of an operational system, wherein the operations of the target asset are affected by the operations of an upstream asset and the operations of the target asset affect the operations of a downstream asset; determining at least one operational anomaly associated with the target asset based on the system data, wherein the operational anomaly is indicative of a difference in operations of the target asset with respect to standard operation; identifying a root cause variable associated with the at least one operational anomaly; determining a first remaining lifetime value for the root cause variable, the first remaining lifetime value representing a time to reach a limit threshold value associated with the root cause variable; determining a second remaining lifetime value for an asset health index representing an overall operational health of the target asset and associated with the target asset based on the first remaining lifetime value, the second remaining lifetime value representing a remaining useful lifetime for the target asset and, wherein the asset health index associated with the target asset impacts operational health of the at least one of the upstream asset and downstream asset; and initiating at least one of a maintenance and repair processes for the target asset based on the first remaining lifetime value and the second remaining lifetime value.
A compound for use in the treatment of diabetic nephropathy, wherein said compound is a multimer comprising at least two peptides, wherein said peptides consist of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant thereof having SEQ ID NO:1 with one amino acid substitution.
surgical instrument comprising : a closure member for applying a closure motion to a movable jaw of the surgical instrument, said closure member comprising: a distal closure tube segment having a closure body defining an outer surface that has a circular cross-sectional shape and an inner surface, said closure body further defining an upper portion comprising an upper wall thickness (UWT) between said outer and inner surfaces and a lower portion comprising a lower wall thickness (LWT) between said outer and inner surfaces, wherein said upper wall thickness (UWT) and said lower wall thickness (LWT) are each measured along a common vertical reference axis (VR) that extends through a center point (C) of said closure body wherein said upper wall thickness (UWT) differs from said lower wall thickness (LWT); and a cam surface formed on a distal end of said upper portion for selective camming contact with a portion of the movable jaw, characterized in that the closure member further comprises diametrically opposed sidewall portions extending between said upper portion and said lower portion and wherein said sidewall portions each have a sidewall thickness (SWT) that is greater than said upper wall thickness (UWT) and said lower wall thickness (LWT), wherein said sidewall thickness (SWT) is measured along a horizontal reference axis (HR) that extends through said center point (C) and is perpendicular to said vertical reference axis (VR). a distal closure tube segment having a closure body defining an outer surface that has a circular cross-sectional shape and an inner surface, said closure body further defining an upper portion comprising an upper wall thickness (UWT) between said outer and inner surfaces and a lower portion comprising a lower wall thickness (LWT) between said outer and inner surfaces, wherein said upper wall thickness (UWT) and said lower wall thickness (LWT) are each measured along a common vertical reference axis (VR) that extends through a center point (C) of said closure body wherein said upper wall thickness (UWT) differs from said lower wall thickness (LWT); and a cam surface formed on a distal end of said upper portion for selective camming contact with a portion of the movable jaw, characterized in that the closure member further comprises diametrically opposed sidewall portions extending between said upper portion and said lower portion and wherein said sidewall portions each have a sidewall thickness (SWT) that is greater than said upper wall thickness (UWT) and said lower wall thickness (LWT), wherein said sidewall thickness (SWT) is measured along a horizontal reference axis (HR) that extends through said center point (C) and is perpendicular to said vertical reference axis (VR).
A post-processing apparatus comprising: a blade that is to be pressed against a recording medium at a folding position where the recording medium is to be folded; a support portion that supports the blade , wherein the support portion comprises a movable body to which the blade is fixed and that moves together with the blade, and an insertion portion that is inserted into the movable body , and the insertion portion and one surface of the movable body are pressed against each other; and an urging member by which the insertion portion and the one surface of the movable body are pressed against each other, characterized in that the urging member presses the movable body . a blade that is to be pressed against a recording medium at a folding position where the recording medium is to be folded; a support portion that supports the blade , wherein the support portion comprises a movable body to which the blade is fixed and that moves together with the blade, and an insertion portion that is inserted into the movable body , and the insertion portion and one surface of the movable body are pressed against each other; and an urging member by which the insertion portion and the one surface of the movable body are pressed against each other, characterized in that the urging member presses the movable body .
A method of resolving an inconclusive cytological assessment of bladder epithelial cells in a sample obtained from a patient, the method comprising contacting cells from the sample with an anti-telomerase antibody, wherein the sample comprises bladder epithelial cells having a cell morphology that is indeterminate of malignancy, and, detecting binding of the antibody to the bladder epithelial cells, wherein binding of the antibody to bladder epithelial cells indicates the presence of malignant bladder epithelial cells.
An apparatus for performing a nucleic acid amplification reaction through a temperature control, the apparatus comprising: (i) a main body ; (ii) at least two blocks positioned on the main body , separated from each other in terms of thermal conduction, and configured to be subjected to independent temperature control; and (iii) a moving module positioned in the main body ; characterized in that each of the at least two blocks has at least one sliding recess and the at least one sliding recess has a straight line shape and the at least one sliding recess of the at least two blocks is aligned with each other, and in that the width of the at least one sliding recess is configured to accommodate a reaction vessel or a reaction vessel holder . (i) a main body ; (ii) at least two blocks positioned on the main body , separated from each other in terms of thermal conduction, and configured to be subjected to independent temperature control; and (iii) a moving module positioned in the main body ;
A computer-implemented heartbeat detection method comprising: a first step (S1) of calculating a heartbeat time from a sampling data string of an electrocardiographic waveform of a living body; a second step (S4) of calculating, for each heartbeat time, a heart rate from the heartbeat time calculated in the first step; and a third step (S5) of calculating, based on the heart rate calculated in the second step, a length of a skip period every time the heartbeat time is calculated, wherein the first step includes a step in which if a time difference between a latest time calculated from the sampling data string and an immediately preceding heartbeat time is not longer than the length of the skip period calculated from the immediately preceding heartbeat time, the latest time calculated from the sampling data string is not adopted as a heartbeat time, characterized in that the third step includes a step in which a variable Y(X) is calculated such that Y(X) - 2(X + ΔX) if X + ΔX ≤ X max /2, Y (X) = (1 + r) (X + ΔX) if X max /2 < X + ΔX ≤ X max /(1 + r), and Y (X) = Y max if X + ΔX > X max /(1 + r), and the length of the skip period is calculated based on a reciprocal of the variable Y(X), wherein X represents the heart rate, X max represents a predetermined possible upper limit value of the heart rate X, ΔX is a constant which represents a variation component of the heart rate X caused by a variation in appearance interval of an R wave, and r is a constant between not less than 0 and less than 1. a first step (S1) of calculating a heartbeat time from a sampling data string of an electrocardiographic waveform of a living body; a second step (S4) of calculating, for each heartbeat time, a heart rate from the heartbeat time calculated in the first step; and a third step (S5) of calculating, based on the heart rate calculated in the second step, a length of a skip period every time the heartbeat time is calculated, wherein the first step includes a step in which if a time difference between a latest time calculated from the sampling data string and an immediately preceding heartbeat time is not longer than the length of the skip period calculated from the immediately preceding heartbeat time, the latest time calculated from the sampling data string is not adopted as a heartbeat time, characterized in that the third step includes a step in which a variable Y(X) is calculated such that Y(X) - 2(X + ΔX) if X + ΔX ≤ X max /2, Y (X) = (1 + r) (X + ΔX) if X max /2 < X + ΔX ≤ X max /(1 + r), and Y (X) = Y max if X + ΔX > X max /(1 + r), and the length of the skip period is calculated based on a reciprocal of the variable Y(X), wherein X represents the heart rate, X max represents a predetermined possible upper limit value of the heart rate X, ΔX is a constant which represents a variation component of the heart rate X caused by a variation in appearance interval of an R wave, and r is a constant between not less than 0 and less than 1.
An air freshener composition, characterized in that the air freshener composition comprises component A and component B, wherein a weight ratio of the component A to the component B is 1: 0.5-3; the component A comprises, in parts by weight, 10-30 parts by weight of an active agent, 6-15 parts by weight of a carrier, 1-4 parts by weight of a pH regulator, and 0.01-0.2 part by weight of an antioxidant; the active agent comprises a compound containing at least two hydroxyl groups; and the carrier comprises an organic acid having 16-24 carbon atoms; and the component B is a plant extract solution, wherein the plant extract solution comprises at least, in parts by weight: 5-30 parts by weight of an extract of a mixture of Populus nigra var. italica, grapefruit peels and eucalyptus leaves; 0.1-5 parts by weight of Sophora flavescens extract; 1-3 parts by weight of Aloe vera extract; 1-10 parts by weight of fresh orange peel extract; 0.5-3 parts by weight of Nandina domestica extract; 0.5-10 parts by weight of Eucalyptus robusta Smith extract; 1-8 parts by weight of Robinia pseudoacacia L. extract; 1-5 parts by weight of Chrysanthemum morifolium extract, and 0.1-2 parts by weight of artemisinin; wherein the active agent is selected from a combination of any one or more of ethylene glycol, propylene glycol, butylene glycol, polyethylene glycol, glycerol and 1,3,5-cyclohexanetriol; the carrier is selected from a combination of any one or more of palmitic acid, stearic acid, arachidic acid and behenic acid; the pH regulator is selected from a combination of any one or more of sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium bicarbonate and disodium hydrogen phosphate.
A computer-implemented method comprising: initiating a deployment of a first virtual machine in parallel with deployment of a second virtual machine; and after the deployment of the first virtual machine has begun, determining that the deployment of a first virtual machine has halted; characterized in that determining, using a dependency controller , that the deployment of the first virtual machine has halted is based on a wait request sent from the first virtual machine to the dependency controller because the deployment of the first virtual machine has reached a point at which the deployment of the first virtual machine is dependent on the second virtual machine that has not been fully deployed; wherein the first virtual machine is instrumented with an instruction to await availability of the second virtual machine by sending the wait request; and wherein the second virtual machine is instrumented with an instruction to send a notify request to the dependency controller when deployment of the second virtual machine 114B is completed; the method further comprising detecting, using the dependency controller , that the second virtual machine has been deployed; and in response to the detecting that the second virtual machine has been deployed, notifying, via the dependency controller , the first virtual machine that deployment of the first virtual machine may continue. initiating a deployment of a first virtual machine in parallel with deployment of a second virtual machine; and after the deployment of the first virtual machine has begun, determining that the deployment of a first virtual machine has halted; characterized in that determining, using a dependency controller , that the deployment of the first virtual machine has halted is based on a wait request sent from the first virtual machine to the dependency controller because the deployment of the first virtual machine has reached a point at which the deployment of the first virtual machine is dependent on the second virtual machine that has not been fully deployed; wherein the first virtual machine is instrumented with an instruction to await availability of the second virtual machine by sending the wait request; and wherein the second virtual machine is instrumented with an instruction to send a notify request to the dependency controller when deployment of the second virtual machine 114B is completed; the method further comprising detecting, using the dependency controller , that the second virtual machine has been deployed; and in response to the detecting that the second virtual machine has been deployed, notifying, via the dependency controller , the first virtual machine that deployment of the first virtual machine may continue.
A method for selecting an immunoglobulin able to bind in an intracellular environment to a post-translationally modified target or for determining the ability of an immunoglobulin to bind in an intracellular environment to a post-translationally modified target, said method comprising the steps of: a) providing a nucleic acid encoding for an intracellular immunoglobulin which is associated with a first molecule; and b) providing a nucleic acid encoding for an intracellular target which is: - fuse to an enzyme that modifies in vivo the target or - subjected to a direct site-specific genetic encoding of the Post-Translational Modifications (PTM) into the target protein and - a second molecule, wherein said first and second molecules are separable domains of a reporter molecule; and c) expressing said first nucleotide sequence together with said second nucleotide sequence in an intracellular environment, wherein binding of said immunoglobulin with said target leads to stable interaction of the first molecule and second molecule, thus producing a detectable reporter molecule that generates a signal, and d) detecting said signal from said detectable reporter molecule, wherein said detection of a signal is indicative of stable binding activity between said immunoglobulin and said target in the intracellular environment; e) isolating those immunoglobulins that stably bind to the target and optionally f) selecting those immunoglobulins that do not bind to target that is not post-translationally modified. a) providing a nucleic acid encoding for an intracellular immunoglobulin which is associated with a first molecule; and b) providing a nucleic acid encoding for an intracellular target which is: - fuse to an enzyme that modifies in vivo the target or - subjected to a direct site-specific genetic encoding of the Post-Translational Modifications (PTM) into the target protein and - a second molecule, wherein said first and second molecules are separable domains of a reporter molecule; and - fuse to an enzyme that modifies in vivo the target or - subjected to a direct site-specific genetic encoding of the Post-Translational Modifications (PTM) into the target protein and - a second molecule, c) expressing said first nucleotide sequence together with said second nucleotide sequence in an intracellular environment, wherein binding of said immunoglobulin with said target leads to stable interaction of the first molecule and second molecule, thus producing a detectable reporter molecule that generates a signal, and d) detecting said signal from said detectable reporter molecule, wherein said detection of a signal is indicative of stable binding activity between said immunoglobulin and said target in the intracellular environment; e) isolating those immunoglobulins that stably bind to the target and optionally f) selecting those immunoglobulins that do not bind to target that is not post-translationally modified.
A monocrystalline SiC substrate with an asymmetric shape for enhancing substrate stiffness against thermal induced deformations, the substrate comprising: a main region; and an asymmetric region located at a peripheral region of the substrate and adjacent to the main region, wherein the asymmetric region is inclined inwards, relative to the main region, to provide an asymmetric shape to the substrate; wherein the asymmetric region is delimited between a substrate rim and the main region, and wherein the asymmetric region joins the main region in a continuous manner, the inclination between the asymmetric and main regions defining an elbow or shoulder in the asymmetric shape of the substrate. a main region; and an asymmetric region located at a peripheral region of the substrate and adjacent to the main region, wherein the asymmetric region is inclined inwards, relative to the main region, to provide an asymmetric shape to the substrate; wherein the asymmetric region is delimited between a substrate rim and the main region, and wherein the asymmetric region joins the main region in a continuous manner, the inclination between the asymmetric and main regions defining an elbow or shoulder in the asymmetric shape of the substrate.
An electromagnetic shock pump, comprising: a valve body , which is provided with a center hole; a pressure relief valve, which is provided in the center hole; a piston , comprising a piston head provided within the center hole, an end of the free end of the piston head is provided with a sealing member , wherein the sealing member is pressed against a hole wall of the center hole, and the sealing member is able of moving along an axial direction of the center hole in a synchronized manner with the piston head ; a water-sucking valve, which is provided on the piston head , and provided opposite to the pressure relief valve; wherein, the pressure relief valve, the valve body , the piston head , the sealing member and the water-sucking valve form a sealed space; wherein, an annular flange is arranged on the inner wall of the center hole, and the pressure relief valve comprises a first valve spool and a spring, the spring is pressed against the first valve spool so as to make the first valve spool move to a position where the first valve spool seats on the annular flange . a valve body , which is provided with a center hole; a pressure relief valve, which is provided in the center hole; a piston , comprising a piston head provided within the center hole, an end of the free end of the piston head is provided with a sealing member , wherein the sealing member is pressed against a hole wall of the center hole, and the sealing member is able of moving along an axial direction of the center hole in a synchronized manner with the piston head ; a water-sucking valve, which is provided on the piston head , and provided opposite to the pressure relief valve; wherein, the pressure relief valve, the valve body , the piston head , the sealing member and the water-sucking valve form a sealed space; wherein, an annular flange is arranged on the inner wall of the center hole, and the pressure relief valve comprises a first valve spool and a spring, the spring is pressed against the first valve spool so as to make the first valve spool move to a position where the first valve spool seats on the annular flange .
A composition for use in the treatment of diseases caused by increase in GM-CSF concentration, wherein the disease is selected from the group consisting of immune-mediated demyelinating disease, multiple sclerosis, chronic organ inflammation, and rheumatoid arthritis, the composition comprising -1-O-(α-D-galactosyl)-2-(N-tetracosanoylamino)-1,3,4-nonanetriol as an active ingredient; wherein the composition is used such that 0.01 mg or larger and 50 mg or smaller of -1-O-(α-D-galactosyl)-2-(N-tetracosanoylamino)-1,3,4-nonanetriol per dosage is orally administered to a human in a dose interval of once in 1 to 7 days.